<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00829075</url>
  </required_header>
  <id_info>
    <org_study_id>VLC-MM-0501-37</org_study_id>
    <nct_id>NCT00829075</nct_id>
  </id_info>
  <brief_title>Impact of Three Different Gonadotrophin Regimes on Egg Donation Program</brief_title>
  <official_title>A Prospective, Randomized, Controlled Trial Comparing Three Different Gonadotrophin Regimens in Oocyte Donors: Ovarian Response and IVF Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Valenciano de Infertilidad, IVI VALENCIA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Valenciano de Infertilidad, IVI VALENCIA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exploratory study assessing the effect of three gonadotrophin protocols on Controlled Ovarian
      Stimulation (COS) parameters and IVF outcome in oocyte donors undergoing GnRH analogue (long
      protocol). 1,028 donors were randomized in three groups: Group I (n= 346) only r-FSH, Group
      II (n= 333) only HP-hMG and Group III (n= 349) r-FSH plus HP-hMG. IVF outcome of 1,059 oocyte
      recipients was compared.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>The aim of this study was to verify whether different gonadotrophin regimes could affect controlled ovarian stimulation (COS) parameters and IVF outcome in an egg donation program.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <condition>Ovarian Stimulation</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>only r-FSH TREATMENT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>only HP-hMG TREATMENT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>r-FSH plus HP-hMG TREATMENT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>r-FSH</intervention_name>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HP-hMG</intervention_name>
    <arm_group_label>II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>r-FSH plus HP-hMG</intervention_name>
    <arm_group_label>III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy women 18-34 years of age

          -  regular menstrual cycles

          -  no family history of hereditary or chromosomal diseases

          -  normal karyotype

          -  BMI 18-29 Kg/m2

          -  negative screening for sexually transmitted diseases

        Exclusion Criteria:

          -  women with PCOS were not included in this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>34 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Melo, MDPhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IVI Valencia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IVI Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2009</study_first_submitted>
  <study_first_submitted_qc>January 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2009</study_first_posted>
  <last_update_submitted>January 23, 2009</last_update_submitted>
  <last_update_submitted_qc>January 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Marco Melo</name_title>
    <organization>IVI Valencia</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

